Two people survive the same event. One processes it, grieves, and moves forward. The other develops PTSD that reorganizes their life. The difference is not willpower, and it is not the severity of what happened alone. A large part of it is biological, and in the last decade the biology has become specific enough to name.
As a trauma psychiatrist Austin, Dr. Lauren Williams sees this pattern across trauma evaluations. The people most confused by their own symptoms are often the high-functioning ones. They ask a version of the same question: It wasn’t even that bad, so why can’t I get over it? The answer is that “getting over it” is a neurobiological process, fear extinction, and that process runs differently depending on a person’s genetics and the epigenetic marks their history has already left on their stress system.
This is not abstract. It explains why trauma is not one-size-fits-all, why it concentrates in some families, and why women carry roughly twice the lifetime PTSD risk of men.
The brain process underneath PTSD: fear extinction
When something threatening happens, the brain learns the threat fast. That is adaptive. What is supposed to happen afterward is extinction: the prefrontal cortex gradually teaches the fear centers that the threat is over, and the alarm stands down.
In PTSD, extinction fails. The fear learning stays switched on. The prefrontal cortex cannot adequately quiet the amygdala, and the body keeps responding to a danger that has passed. So the relevant question for an evaluation is not only “what happened to you” but “how does your brain’s extinction machinery actually work” – because that machinery is partly written in your biology.
Two layers of that biology matter most, and they are different in kind. One is the fixed gene you inherited. The other is the modifiable epigenetic layer your experience wrote on top of it.
Layer one: COMT, the inherited setting on fear extinction
COMT, short for catechol-O-methyltransferase, is a gene that codes for an enzyme that clears dopamine from the prefrontal cortex. A common variation in it, called Val158Met, changes how fast that clearance happens, which changes how well the prefrontal cortex performs the fear-extinction job.
The research is reasonably consistent on the direction: the slow-clearing “Met/Met” variant is associated with reduced ability to extinguish conditioned fear and, in multiple studies, higher PTSD risk after trauma. But here is the part that keeps the science honest, and that I emphasize with patients: COMT is not “the PTSD gene.” Its effect is a gene-by-environment interaction. In a large study of Marines, the Met/Met fear-inhibition deficit appeared specifically in those with childhood trauma exposure, and there was no COMT-fear association in healthy, non-traumatized people. The genotype loads the spring; trauma is what releases it. And risk rises with traumatic load in a dose-response way, the genetic variant shifting the odds rather than determining the outcome.
That framing matters because it is both more accurate and less fatalistic. A variant is a susceptibility, not a sentence.
Layer two: DNA methylation, the mark trauma leaves
The second layer is epigenetic, and it is where the most active PTSD research is happening. DNA methylation is a chemical tag the body places on genes to turn their expression up or down. Crucially, it is modifiable: experience writes it, and it can change over time. Trauma, especially early-life trauma, leaves methylation marks on the genes that run the stress system.
Two genes dominate this literature, both governing the HPA axis, the body’s central stress-response circuit:
- NR3C1, which codes for the glucocorticoid receptor, the molecule that lets the body sense cortisol and switch the stress response off. Childhood adversity is associated with altered methylation of NR3C1, which can blunt that off-switch.
- FKBP5, which regulates the glucocorticoid receptor’s sensitivity. This is the strongest finding in the field: in a landmark study, people carrying an FKBP5 risk variant and a history of childhood trauma showed reduced methylation of key regulatory regions, driving increased FKBP5 expression and a stress system that resists shutting off. The effect was specific to childhood trauma, independent of trauma in adulthood, pointing to a developmental window when the marks get written.
Put the two layers together and you have a coherent picture. The HPA axis is supposed to mount a stress response and then return to baseline. Trauma-driven methylation changes can leave that system stuck in a state of glucocorticoid resistance, where the off-switch works poorly, while an inherited COMT setting can leave the prefrontal cortex less able to run extinction. Different mechanisms, same lived result: a brain that learned a threat and cannot fully unlearn it.
Why this shows up differently in women
Women have a higher lifetime prevalence of PTSD than men, and the biology above helps explain part of why, beyond differences in trauma exposure.
The clearest thread is estrogen’s effect on fear extinction. Estradiol supports the same dopaminergic prefrontal function that COMT governs, and research shows a COMT-by-sex interaction: when estrogen is higher, women extinguish conditioned fear more effectively; the genotype’s effect on fear memory plays out differently across the sexes through this hormonal channel. The practical implication is significant. Fear-extinction capacity is not fixed across the month or across a woman’s reproductive life. It can shift with the menstrual cycle, where the low-estradiol late luteal phase may be a window of reduced extinction capacity, and across pregnancy, postpartum, and perimenopause, when estradiol changes substantially. A trauma processed during a low-estrogen window may consolidate differently than the same event in a high-estrogen one.
This connects trauma to the same hormonal-sensitivity thread that runs through PMDD, postpartum anxiety, and perimenopausal mood change: the female stress and fear systems are not hormonally static, and an evaluation that ignores that is working with half the picture.
There is also an intergenerational layer that lands disproportionately on women, because pregnancy is where some of this transmission happens. Studies of trauma-exposed mothers show correlations between maternal and child methylation of these same stress-axis genes. A woman’s own trauma history is therefore not only her concern; the stress-axis programming can carry forward, which is an argument for treating it, not a reason for alarm.
What this does and does not mean for your care
I want to be precise about the clinical reality, because this is a field where the science gets oversold.
What this does not mean: it does not mean a genetic test or a methylation panel can diagnose your PTSD, predict your course, or pick your treatment. Those tests are research tools right now, not validated clinical instruments for the individual. Anyone selling you a methylation test as a PTSD diagnosis is ahead of the evidence, and I won’t.
What it does mean: the biology reframes how a careful trauma evaluation should be conducted. It means understanding your developmental and trauma history as the thing that shaped your stress system, not as background. It means accounting for the hormonal context that modulates your fear extinction, which for women is not a side issue. It means recognizing that the comorbidities trauma travels with, the anxiety, the depression, the sleep collapse, the hormonal sensitivity, are part of one dysregulated stress system, not a list of separate problems. And it means treating with the mechanism in view.
The most encouraging part of the research points exactly this direction: epigenetic marks on these stress genes have been associated with response to psychotherapy for PTSD. The methylation that trauma writes is not necessarily permanent, and effective treatment appears to move the very biology this article describes. The fear that was learned can, with the right work, be unlearned. That is the whole premise of treatment.
How I approach trauma
A trauma evaluation here is not a symptom checklist and a prescription. It is a structured assessment built on the biology above:
- Developmental and trauma history, mapped as the origin of how your stress system is currently set, including early-life adversity that may have left the deepest marks.
- Full differential and comorbidity mapping, because trauma rarely arrives alone and the related conditions share the dysregulated stress axis.
- Hormonal context, especially for women, because fear extinction and stress reactivity shift with the reproductive stage and the cycle.
- Biological screening, because thyroid dysfunction, nutrient status, sleep, and inflammation all modulate a stress system already under strain.
- Treatment architecture, sequencing evidence-based trauma therapy and, where indicated, medication, with the understanding that the goal is to help the nervous system complete the extinction it got stuck on.
Where a person’s genetic or biological profile is known, I let it inform the strategy rather than ignore it. The same variations that shape how a stress system holds onto fear also have implications for how I’d support that system, including targeted, evidence-supported nutritional and adjunctive approaches matched to the individual’s biology and chosen to work alongside trauma therapy, never in place of it. That tailoring is part of what the evaluation is for. It is not a protocol I’d hand someone off the shelf, because the entire point is that it is built for the specific system in front of me.
Who this is for
If you have asked yourself why an event that “wasn’t that bad” still has a grip on your nervous system, if you want the mechanism rather than a platitude, if you’d rather work with someone who treats your history and your biology as the actual subject: I built this work for you.
If what you need is urgent or crisis care, that requires a different and more immediate setting, and you deserve the right one for this moment. If you are in crisis or having thoughts of harming yourself, call or text 988 or go to the nearest emergency department.
I keep a deliberately small roster so each trauma evaluation can be this thorough. That’s by design.
The practice
Dr. Lauren Williams is a board-certified trauma psychiatrist Austin, Texas, evaluating and treating PTSD and trauma-related conditions in high-functioning adults, with particular attention to the biological and hormonal mechanisms that shape how trauma takes hold. Care is structured around comprehensive psychiatric and biological evaluation; brief medication management is not the model.
If this article described something you recognize, you may request a consultation. We’ll both find out if it’s a fit.
Patient's Most Asked Questions
Why do some people develop PTSD from trauma and others don't?
Risk depends on an interaction between biology and experience, not on willpower or severity alone. Inherited variation (such as the COMT gene) affects how well the brain extinguishes fear, and trauma leaves epigenetic marks (DNA methylation) on stress-system genes like FKBP5 and NR3C1 that can keep the stress response from shutting off. Genetics shifts the odds; trauma exposure determines whether that susceptibility is expressed.
What is DNA methylation and how is it related to PTSD?
DNA methylation is a chemical tag that turns gene expression up or down, and unlike fixed DNA sequence it can change with experience. Trauma, especially in early life, alters methylation of HPA-axis genes (FKBP5, NR3C1) that regulate the cortisol stress response, which is associated with PTSD risk. Encouragingly, these marks are modifiable, and effective psychotherapy has been associated with changes in them.
Does COMT cause PTSD?
No single gene causes PTSD. The COMT Val158Met variant is associated with reduced fear extinction and higher PTSD risk, but only as a gene-by-environment interaction, primarily in people with trauma exposure. It is a susceptibility factor, not a determinant.
Why are women more likely to develop PTSD?
Women have roughly twice the lifetime PTSD prevalence of men, partly due to a hormonal mechanism: estrogen supports the prefrontal fear-extinction system, and fear-extinction capacity shifts with estradiol across the menstrual cycle and reproductive life. Trauma processed during a low-estrogen window may consolidate differently. Exposure differences and an intergenerational stress-axis component also contribute.
Can a genetic or methylation test diagnose my PTSD?
No. Genetic and methylation findings are research tools, not validated clinical tests for diagnosing PTSD or selecting treatment in an individual. A thorough clinical evaluation remains the standard; the biology informs how that evaluation is conducted, not a lab-based shortcut.
Who is a trauma psychiatrist in Austin?
Dr. Lauren Williams evaluates and treats PTSD and trauma-related conditions in adults in Austin, Texas, with attention to the biological and hormonal mechanisms underlying trauma, in a comprehensive private-pay evaluation model.
